Razak AR - Search Results

1

Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents.

Le Tourneau C, Gan HK, Razak AR, Paoletti X. Le Tourneau C, et al. Among authors: razak ar. PLoS One. 2012;7(12):e51039. doi: 10.1371/journal.pone.0051039. Epub 2012 Dec 12. PLoS One. 2012. PMID: 23251419 Free PMC article.

2

Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.

Marous M, Bièche I, Paoletti X, Alt M, Razak AR, Stathis A, Kamal M, Le Tourneau C. Marous M, et al. Among authors: razak ar. Ann Oncol. 2015 Dec;26(12):2419-28. doi: 10.1093/annonc/mdv378. Epub 2015 Sep 14. Ann Oncol. 2015. PMID: 26371283 Free article. Review.

3

Development of anti-cancer drugs.

Arrondeau J, Gan HK, Razak AR, Paoletti X, Le Tourneau C. Arrondeau J, et al. Among authors: razak ar. Discov Med. 2010 Oct;10(53):355-62. Discov Med. 2010. PMID: 21034677 Free article. Review.

4

Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.

Le Tourneau C, Razak AR, Gan HK, Pop S, Diéras V, Tresca P, Paoletti X. Le Tourneau C, et al. Among authors: razak ar. Eur J Cancer. 2011 Jul;47(10):1468-75. doi: 10.1016/j.ejca.2011.03.016. Epub 2011 Apr 7. Eur J Cancer. 2011. PMID: 21482105 Review.

5

Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland.

Le Tourneau C, Razak AR, Levy C, Calugaru V, Galatoire O, Dendale R, Desjardins L, Gan HK. Le Tourneau C, et al. Among authors: razak ar. Br J Ophthalmol. 2011 Nov;95(11):1483-9. doi: 10.1136/bjo.2010.192351. Epub 2010 Dec 22. Br J Ophthalmol. 2011. PMID: 21183517 Review.

6

Molecular targeted therapies in all histologies of head and neck cancers: an update.

Razak AR, Siu LL, Le Tourneau C. Razak AR, et al. Curr Opin Oncol. 2010 May;22(3):212-20. doi: 10.1097/CCO.0b013e328338001f. Curr Opin Oncol. 2010. PMID: 20173639 Review.

7

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Jones SF, Siu LL, Bendell JC, Cleary JM, Razak AR, Infante JR, Pandya SS, Bedard PL, Pierce KJ, Houk B, Roberts WG, Shreeve SM, Shapiro GI. Jones SF, et al. Among authors: razak ar. Invest New Drugs. 2015 Oct;33(5):1100-7. doi: 10.1007/s10637-015-0282-y. Epub 2015 Sep 4. Invest New Drugs. 2015. PMID: 26334219 Clinical Trial.

8

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.

Diaz-Padilla I, Siu LL, San Pedro-Salcedo M, Razak AR, Colevas AD, Shepherd FA, Leighl NB, Neal JW, Thibault A, Liu L, Lisano J, Gao B, Lawson EB, Wakelee HA. Diaz-Padilla I, et al. Among authors: razak ar. Br J Cancer. 2012 Aug 7;107(4):604-11. doi: 10.1038/bjc.2012.319. Epub 2012 Jul 17. Br J Cancer. 2012. PMID: 22805331 Free PMC article. Clinical Trial.

9

Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs.

Bugano DDG, Hess K, Jardim DLF, Zer A, Meric-Bernstam F, Siu LL, Razak ARA, Hong DS. Bugano DDG, et al. Clin Cancer Res. 2017 Aug 1;23(15):4020-4026. doi: 10.1158/1078-0432.CCR-16-2354. Epub 2017 Apr 4. Clin Cancer Res. 2017. PMID: 28377482 Free PMC article.

10

Nasopharyngeal carcinoma: the next challenges.

Razak AR, Siu LL, Liu FF, Ito E, O'Sullivan B, Chan K. Razak AR, et al. Eur J Cancer. 2010 Jul;46(11):1967-78. doi: 10.1016/j.ejca.2010.04.004. Epub 2010 May 5. Eur J Cancer. 2010. PMID: 20451372 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135 results

Search Page

Filters